Gene therapy administration: A collaborative model for complex care
Sarah Hale
Geisinger continues to expand its capabilities in delivering advanced therapies. Among the most notable are gene therapies for pediatric patients, including onasemnogene abeparvovec-xioi (Zolgensma) for spinal muscular atrophy (SMA) and delandistrogene moxeparvovec-rokl (Elevidys) for Duchenne muscular dystrophy (DMD). These treatments represent some of the most complex